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Abstract
Introduction: Primary Sjögren’s syndrome (pSS) is a chronic autoimmune disease with complex etiopathogenesis.
Despite extensive studies to understand the disease process utilizing human and mouse models, the intersection
between these species remains elusive. To address this gap, we utilized a novel systems biology approach to
identify disease-related gene modules and signaling pathways that overlap between humans and mice.
Methods: Parotid gland tissues were harvested from 24 pSS and 16 non-pSS sicca patients and 25 controls. For
mouse studies, salivary glands were harvested from C57BL/6.NOD-Aec1Aec2 mice at various times during
development of pSS-like disease. RNA was analyzed with Affymetrix HG U133+2.0 arrays for human samples and
with MOE430+2.0 arrays for mouse samples. The images were processed with Affymetrix software. Weighted-gene
co-expression network analysis was used to identify disease-related and functional pathways.
Results: Nineteen co-expression modules were identified in human parotid tissue, of which four were significantly
upregulated and three were downregulated in pSS patients compared with non-pSS sicca patients and controls.
Notably, one of the human disease-related modules was highly preserved in the mouse model, and was enriched
with genes involved in immune and inflammatory responses. Further comparison between these two species led
to the identification of genes associated with leukocyte recruitment and germinal center formation.
Conclusion: Our systems biology analysis of genome-wide expression data from salivary gland tissue of pSS
patients and from a pSS mouse model identified common dysregulated biological pathways and molecular targets
underlying critical molecular alterations in pSS pathogenesis.
Introduction
Sjögren’s syndrome is a chronic, inflammatory autoim-
mune disease characterized by lymphocytic infiltration
of the exocrine glands, especially the salivary and lacri-
mal glands, leading to destruction of their functional
components. The disease may exist alone as primary
Sjögren’s syndrome (pSS) or in conjunction with
another autoimmune disorder as secondary Sjögren’s
syndrome [1]. The disease affects 0.5 to 1.0% of the
general population and shows a striking 9:1 female pre-
dominance [2,3]. Although dry mouth and dry eyes are
the hallmark symptoms of pSS, the disease can affect
almost any organ of the body and can cause substantial
morbidity [4]. Symptomatic therapy currently dominates
the overall management of affected individuals [5,6].
The diagnostic criteria, including the American-Eur-
opean Consensus Group (AECG) criteria involving
either serology or histopathology in conjunction with
oral and ocular dryness [7], are often inconsistently
applied, and are not optimal in differentiating pSS from
non-pSS sicca patients or addressing extraglandular
manifestations. As a result, diagnosis of Sjögren’s syn-
drome often lags disease onset by 6 to 10 years. Recent
* Correspondence: dtww@ucla.edu
† Contributed equally
1School of Dentistry, Dental Research Institute, University of California at Los
Angeles, 10833 Le Conte Avenue, 73-017 CHS, Los Angeles, CA 90095-1668,
USA
Full list of author information is available at the end of the article
Horvath et al. Arthritis Research & Therapy 2012, 14:R238
http://arthritis-research.com/content/14/6/R238
© 2012 Horvath et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
attempts to address these issues - the EULAR Sjögren’s
Syndrome Patient Reported Index, and a disease activity
index to evaluate systemic complications (EULAR Sjög-
ren’s Syndrome Disease Activity Index) [8,9] - require
further large-scale validation. In addition to the difficulty
in disease diagnosis, the underlying pathophysiologic
mechanisms of Sjögren’s syndrome remain obscure.
A common model suggests interaction between
genetic susceptibility and environmental factors such as
viral infections for the immune cell activation and pro-
tracted inflammatory response resulting in glandular
dysfunction and systemic autoimmunity [6]. In addition,
recent studies in human and animal models have high-
lighted several components of the innate and adaptive
immune systems as well as nonimmunologic factors
[10-13]. However, there is a general lack of experimental
and research intersections between humans and mouse
models in terms of biological pathways and key molecu-
lar targets. Indeed, a wide variety of animal models of
Sjögren’s syndrome have been described; each capturing
certain aspects of the disease [14]. The most widely
used mouse model, NOD, exhibits CD4+ lymphocyte
infiltration, autoantibodies, xerostomia and a female-
dominant phenotype. However, the mice also develop
diabetes, which complicates the search for Sjögren’s syn-
drome specific changes of gene expression. Recently, the
modified NOD mouse model C57BL/6.NOD-Aec1Aec2
has been described. These mice develop the symptoms
of Sjögren’s syndrome but not diabetes [15], suggesting
that they will be a highly valuable model for understand-
ing the pathogenesis pSS.
In the present study, we applied weighted gene co-
expression network analysis (WGCNA) [16] to charac-
terize biological pathways and molecular targets asso-
ciated with pSS pathogenesis in both human parotid
tissue and the C57BL/6.NOD-Aec1Aec2 mouse model.
Our systems analysis of genome-wide expression data
from human (pSS) salivary gland tissue compared with
salivary gland tissue from a mouse model of pSS identi-
fied common biological pathways and molecular targets
that can pivotally contribute to critical molecular altera-
tions in pSS pathogenesis.
Materials and methods
Human studies
The study protocol was approved by the Institutional
Review Board of the University of California at Los
Angeles and the University Medical Center at Gronin-
gen. All patients were recruited from the Department of
Oral and Maxillofacial Surgery of the University Medical
Center at Groningen, were at least 21 years old, and
provided written informed consent to participate in the
study. The study included 24 patients who fulfilled the
2002 AECG criteria for pSS [17], 16 non-sicca patients
with subjective symptoms and objective signs of oral
and ocular dryness but not fulfilling the AECG criteria
for pSS, and 25 control patients with no subjective or
objective evidence of oral or ocular dryness. The patient
characteristics are presented in Table 1.
Parotid gland tissue specimens
Under local anesthesia, an incisional biopsy of one paro-
tid gland was performed as part of the diagnostic
workup of the pSS and non-pSS sicca patients following
AECG criteria, as described [7], and according to the
procedure described by Pijpe and colleagues [18]. Tissue
was harvested from the dorsal caudal lobe of the parotid
gland from the control patients during surgery for oral
or oropharyngeal squamous cell carcinoma.
After harvest, most of the specimen was snap-frozen
and delivered to the University of California at Los
Angeles on dry ice and then stored at -80°C for gene
expression profiling. A minor part was fixed in 4% for-
malin, embedded in paraffin, sectioned, and stained with
H & E for histopathologic evaluation. The evaluation of
slides from pSS and non-pSS sicca patients was per-
formed independently by two oral pathologists, who
determined the focus score (≥50 lymphocytes/4 mm2
glandular tissue) and other characteristics such as lym-
phoepithelial lesions, germinal centers, fibrosis, atrophy,
and so forth. The specimens from pSS patients showed
characteristic features (for example, focus score ≥1 and
presence of lymphoepithelial lesions) whereas those
from non-pSS sicca and control subjects did not show
any such characteristics. Histopathologic evaluation of
parotid tissue from controls revealed no carcinoma.
Gene expression profiling
The isolation of total RNA from snap-frozen parotid
gland tissues, in sample sizes ranging from 10 to 30 mg,
was performed using the RNeasy kit supplied with the
PARIS system (Ambion, Austin, TX, USA), according to
the manufacturer’s protocol. Briefly, each frozen tissue
specimen was homogenized in 300 μl cold cell-disrup-
tion buffer and an equal volume of 2 × denaturing solu-
tion was added. The total lysate was centrifuged for 5
minutes at 10,000 × g to separate out the superficial
aqueous phase containing RNA and then 1.25 volumes
of 100% ethanol were added. The mixture was loaded
onto a spin column followed by washing twice with pro-
vided buffer. RNA was eluted at 100°C into 50 μl elution
buffer. The resultant RNA was subjected to RNase-free
DNase treatment followed by ethanol precipitation, dis-
solved into 15 μl DNase/RNase-free water, and quanti-
fied with a Nanodrop spectrophotometer (Nanodrop
Technology, Wilmington, DE, USA).
The RiboAmp RNA Amplification system (Molecular
Devices, Sunnyvale, CA, USA) was used to perform one
round of linear amplification of parotid gland tissue
mRNAs, taking 2.5 μg total RNA from each specimen as
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the template. The synthesized cDNA was transcribed to
cRNA and then biotinylated using the GeneChip
Expression 3’-Amplification reagents (Affymetrix, Santa
Clara, CA, USA) for in vitro labeling. Then 15 μg
labeled cRNA was fragmented into 50 to 200 bp frag-
ments and assessed for quality with a 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA, USA).
The fragmented biotin-labeled cRNA from pSS, non-
pSS sicca and control subjects was hybridized overnight
to the Affymetrix HG U133 plus 2.0 arrays. After wash-
ing to remove the unbound transcripts, the hybridized
chips were stained prior to scanning. The acquired
images were processed with Affymetrix Microarray Suite
software and analyzed with the R software (which is
freely available at [19]).
Mouse studies
Mouse model of Sjögren’s syndrome-like disease
C57BL/6.NOD-Aec1Aec2 mice were bred and main-
tained under specific pathogen-free conditions within
the mouse facility of the Department of Pathology at the
University of Florida, Gainesville. The breeding and use
of these animals for the present studies were approved
by the University of Florida Institutional Animal Care
and Use Committee. The animals were maintained on a
12-hour light-dark schedule and provided with food and
acidified water ad libitum.
Generation of salivary gland transcriptome data
Salivary glands were freshly excised from euthanized
mice (n = 5 per age group) at 4, 8, 12, 16, or 20 weeks
of age, snap-frozen in liquid nitrogen, and stored at -80°
C until all glandular samples were obtained. Each sali-
vary gland was comprised of a submandibular, sublin-
gual, and parotid gland minus salivary lymph nodes.
Total RNA was isolated from salivary glands of each
mouse using the RNeasy Mini-Kit (Qiagen, Valencia,
CA, USA), in accordance with the manufacturer’s proto-
col. Hybridizations were carried out with each of the 25
individual RNA samples using Affymetrix GeneChip
Mouse Genome 430 plus 2.0 Arrays, in accordance with
the manufacturer’s instructions. Each GeneChip con-
tained 45,000 probe sets that analyzed the expression
level of over 39,000 transcripts and variants from over
34,000 well-characterized mouse genes.
Statistical procedures
Microarray data preprocessing
The Affymetrix U133 plus 2.0 microarray data were ana-
lyzed with functions and packages of the statistical soft-
ware R 2.12.0 and Bioconductor 2.7 (which can be
downloaded from [19]). Expression intensity values were
calculated for the 65 Human microarray CEL files (24
pSS, 16 non-pSS sicca and 25 controls) using the mas5
function of the Affy library. Potential array outliers were
identified by studying their interarray correlation. After
removing potential outliers in a completely unbiased
fashion, all 65 samples remained for downstream analy-
sis. After quantile normalization, the ComBat function
was used to correct for batch effects [20]. To summarize
multiple probe sets per gene, we used the default set-
tings of the collapseRows R function [21]. Each of the
20,718 genes on the array was thus represented by the
probe with the highest mean expression value.
Analogous preprocessing steps were applied to the 25
mouse microarray samples corresponding to five differ-
ent time points (weeks 4, 8, 12, 16 and 20, each time
point had five mice). We related mouse genes to human
data using a table of orthologous genes.
Weighted gene co-expression network analysis and
preservation analysis
The statistical analysis software (WGCNA R package)
and R tutorials for constructing a weighted gene co-
expression network can be found in the literature
[16,22]. The WGCNA package first calculates all pair-
wise Pearson’s correlation coefficients across all samples.
In a signed weighted network, the resulting Pearson’s
Table 1 Characteristics of primary Sjögren’s syndrome, nonprimary Sjögren’s syndrome sicca and control subjects
Characteristic pSS (n = 24) Non-pSS sicca (n = 16) Controls (n = 25)
Age (years) 49.0 ± 15.8 52.8 ± 15.4 59.0 ± 12.0
Female:male 21:3 13:3 12:13
Ethnicity 24 Caucasian 16 Caucasian 25 Caucasian
Unstimulated whole saliva (ml/minute) 0.10 ± 0.14 0.12 ± 0.18 NA
Stimulated whole saliva (ml/minute) 0.31 ± 0.35 0.33 ± 0.40 NA
Schirmer’s test (mm) 9.2 ± 7.6 14.8 ± 11.7 NA
Focal score 3.5 ± 1.2 0.5 ± 1.0 0
Sjögren’s syndrome - A (positive:negative) 23:1 2:14 0:25
Sjögren’s syndrome - B (positive:negative) 19:5 0:16 0:25
Data presented as the mean ± standard deviation. All primary Sjögren’s syndrome (pSS) and non-pSS sicca patients were subjected to a complete American-
European Consensus Group diagnostic work-up. NA, not assessed (in controls being head and neck cancer patients without parotid involvement, no functional
tests were performed as all these patients were already scheduled for a neck dissection and functional tests were considered too much of a burden to the
patients at that time).
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correlation matrix is transformed into an adjacency
matrix [23]:
a(ij) = |0.5 + 0.5 ∗ cor(x(i), x(j))|β)
The default value of the power b = 12 facilitates a
soft-thresholding approach that preserves the continu-
ous nature of the co-expression relationships [16]. As a
network dissimilarity measure we used 1 - the topologi-
cal overlap measure as the input for average linkage
hierarchical clustering [24]. We used the dynamic
branch cutting method to define modules as branches of
the hierarchical clustering tree [25]. Unassigned back-
ground genes, outside each of the modules, were
denoted with the color grey. To group the 20,718 genes
into modules, we used the blockwiseModule R function
in the WGCNA R package.
Connectivity and module membership measures
Module membership (MM), also known as eigengene-
based connectivity, is a measure of intramodular con-
nectivity [26]. MM is defined as:
MM(i) = cor(x(i),ME)
where x(i) is the expression profile of ith gene and ME
is the eigengene (first principal component) of the given
module. We used the MM measure to select module
genes for a gene ontology (GO) enrichment analysis.
The MM measures of the human modules are reported
in Additional file 1.
Functional enrichment analysis
The Database for Annotation, Visualization, and Inte-
grated Discovery (available at [27]) and the Ingenuity
Pathways Analysis software (Ingenuity Systems available
at [28]) were used to determine whether sets of genes
(for example, preserved intramodular hub genes) were
significantly enriched with known GOs. The Ingenuity
software only reports uncorrected P values. The func-
tional enrichment results are reported in Additional file
2.
Module preservation analysis
To evaluate which human modules could also be found
in the mouse data, we used module preservation statis-
tics implemented in the modulePreservation R function
[17]. For each module in the reference data (for exam-
ple, human data), a permutation test leads to the Zsum-
mary statistic in the test data (here the mouse dataset).
Zsummary >10 indicates strong evidence of preservation
while Zsummary <2 indicates no preservation according
to the permutation test.
Standard differential expression analysis
To find differentially expressed genes between pairs of
groupings (involving pSS, sicca, controls), we used two
R functions in the WGCNA package (standardScree-
ningBinaryTrait and standardScreeningNumericTrait)
that report P values, false discovery rates (q values), fold
changes and other widely used statistics for selecting
differential expressed genes. Additional file 3 reports the
differential expression results in humans for studying
contrasting pSS versus controls, sicca patients versus
controls, and pSS versus sicca patients, and for relating
expression data to gender in control subjects. Further,
Additional file 3 reports the correlation of each gene
with an ordinal measure of diagnosis (0 = controls, 1 =
sicca, 2 = pSS), which allows the reader to identify
genes that positively or negatively increase with the dis-
ease progression in humans. We also correlated each
mouse gene with time (weeks) to find genes that are
increasing or decreasing as time progresses. These
results (P values, correlations) are reported in Additional
file 4. These results were also used to create Table 2.
Results
Identification of gene co-expression modules in parotid
glands of pSS patients
A signed weighted gene co-expression network was con-
structed based on the 65 human parotid gland tissues
(24 pSS, 16 non-pSS sicca and 25 controls). The
WGCNA method clustered the 20,718 human genes
into 19 distinct gene co-expression modules. Since the
module detection is unbiased and does not make use of
GO information, each of the modules was initially
labeled with a unique color as an identifier (Figure 1).
To define a representative module expression profile
(referred to as the module eigengene), we summarized
the (standardized) gene expression profiles of the mod-
ule eigengene (= first principal component). The module
eigengene can be considered a weighted average of the
module gene expression profiles. To identify disease-
related modules, we correlate each module eigengene
with disease status.
Strikingly, seven out of 19 modules showed significant
differential expression between pSS and control samples,
which reflects the fact that thousands of genes are dif-
ferentially expressed between the two groups. In particu-
lar, we found a highly significant positive correlation
between disease and the Magenta (comprised of 576
genes) module eigengene (r = 0.67, P <2 × 10-7), the
Brown (2,502 genes) module eigengene (r = 0.6, P <6 ×
10-6), the Light-Cyan (349 genes) module eigengene (r =
0.42, P <0.002), and the Grey60 (based on 216 genes)
module eigengene (r = 0.47, P <8 × 10-4). Since a posi-
tive correlation indicates that the corresponding module
genes are overexpressed in the diseased individuals, the
Magenta, Brown, Light-Cyan and Grey60 modules are
comprised of genes overexpressed in pSS samples com-
pared with both non-pSS sicca and controls (Figure 2).
On the contrary, we found a highly significant negative
correlation between disease status and the Turquoise
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Table 2 Genes with concordant progression patterns in human and mouse disease
Progression GeneSymbol corHuman p.Human corMouse p.Mouse MM.magenta
+ ADA 0.57 5.5 × 10-7 0.62 9.2 × 10-4 0.70
+ AIF1 0.51 1.6 × 10-5 0.57 3.1 × 10-3 0.67
+ C1QB 0.54 3.2 × 10-6 0.65 4.6 × 10-4 0.71
+ CASP3 0.59 1.8 × 10-7 0.52 8.2 × 10-3 0.59
+ CYBB 0.63 1.6 × 10-8 0.56 3.4 × 10-3 0.82
+ ENTPD1 0.51 1.2 × 10-5 0.62 8.5 × 10-4 0.66
+ GZMA 0.63 1.7 × 10-8 0.70 1.0 × 10-4 0.72
+ GZMK 0.61 5.8 × 10-8 0.55 4.1 × 10-3 0.63
+ HLA-DQB1 0.53 6.0 × 10-6 0.65 5.0 × 10-4 0.48
+ HLA-DRB1 0.53 5.9 × 10-6 0.74 2.6 × 10-5 0.89
+ IFIT1 0.59 2.6 × 10-7 0.59 1.9 × 10-3 0.43
+ ITGAX 0.51 1.2 × 10-5 0.63 6.8 × 10-4 0.68
+ LY86 0.58 4.4 × 10-7 0.53 6.4 × 10-3 0.78
+ PLEKHA2 0.63 1.5 × 10-8 0.52 7.1 × 10-3 0.87
+ STAT1 0.67 7.2 × 10-10 0.64 5.2 × 10-4 0.60
+ TLR7 0.63 1.6 × 10-8 0.63 6.6 × 10-4 0.61
- ALDH3A2 -0.50 1.8 × 10-5 -0.63 8.0 × 10-4 -0.64
- ANGPTL4 -0.50 1.9 × 10-5 -0.58 2.6 × 10-3 -0.40
- ATP1B1 -0.56 1.0 × 10-6 -0.58 2.5 × 10-3 -0.62
- CPT1A -0.54 4.0 × 10-6 -0.76 8.7 × 10-6 -0.55
- FAF1 -0.54 4.1 × 10-6 -0.55 4.5 × 10-3 -0.58
- NEO1 -0.52 9.6 × 10-6 -0.53 6.9 × 10-3 -0.47
- PALMD -0.50 2.2 × 10-5 -0.64 6.1 × 10-4 -0.65
- PDHA1 -0.58 3.9 × 10-7 -0.63 8.0 × 10-4 -0.71
- PPFIBP2 -0.56 1.2 × 10-6 -0.57 3.2 × 10-3 -0.48
corHuman denotes the correlation of the gene with human progression status (defined as 0 for controls, 1 for sicca, and 2 for primary Sjögren’s syndrome).
corMouse denotes the correlation of the gene with mouse progression status (weeks). p.Human and p.Mouse report the correlation test P values in human and
mouse data, respectively. MM.magenta reports the module membership value of the gene.
Figure 1 Hierarchical cluster trees for detecting modules based on weighted gene co-expression network analysis. All array samples
(primary Sjögren’s syndrome patients, sicca, and controls) were to find co-expression modules. Modules correspond to branches of the trees and
are assigned color categories as indicated by the color band underneath each tree (see Materials and methods). The two panels correspond to
two cluster trees resulting from the blockwiseModules WGCNA R function [21], which was used to circumvent computational challenges. Each
cluster tree thus corresponds to a block of genes.
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(based on 3,981 genes) module eigengene (r = -0.52,
P <10-4), the Grey (based on 3,011 genes) module eigen-
gene (r = -0.41, P < 0.003), and the Salmon (based on
446 genes) module eigengene (r = -0.28, P <0.005). The
Turquoise, Grey and Salmon modules are thus comprised
of genes that are underexpressed in pSS samples com-
pared with both non-pSS sicca and controls (Figure 3).
All of these P values remain highly significant even after
carrying out the most stringent multiple comparison
adjustment (Bonferroni correction) for the number of
modules. This co-expression module-based analysis has a
major advantage over a standard differential gene expres-
sion analyses since it only relates 19 modules to pSS dis-
ease status, alleviating the multiple comparison problem
inherent in the raw data.
For each gene, Additional file 1 reports MM measures
(also known as eigengene-based connectivity) between
genes and modules.
Figure 2 Identification of primary Sjögren’s syndrome disease-related gene modules revealed by weighted gene co-expression
network analysis. Barplots showing the mean value of the module eigengene (y axis) versus human disease progression status (x axis) where 0
denotes healthy controls, 1 denotes nonprimary Sjögren’s syndrome (non-pSS) sicca patients, and 2 denotes pSS patients. Kruskal-Wallis test P
values above the plots show that the module eigengenes of all four modules - Magenta (576 genes), Brown (2,502 genes), Grey60 (216 genes),
and Light-Cyan (349 genes) - are significantly overexpressed in pSS patients compared with both non-pSS sicca patients and controls.
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Preservation of human Magenta module in a mouse
Sjögren’s syndrome model
We applied the modulePreservation R function to assess
whether modules defined by the human data were pre-
served in C57BL/6.NOD-Aec1Aec2 mice, Sjögren’s syn-
drome-like disease model datasets. We selected the
C57BL/6.NOD-Aec1Aec2 mice for the comparative gene
expression analysis because it is a spontaneous disease
model, probably the best-defined mouse model to date
with respect to its disease profile, and has a comparative
control with the same genetic background that mimics
virtually all molecular and clinical aspects defined in
Figure 3 Primary Sjögren’s syndrome disease-related co-expression modules that are downregulated in primary Sjögren’s syndrome
patients. Barplots analogous to those described in Figure 2. The module eigengenes of two modules - Turquoise (3,981 genes) and Grey (3,011
genes) - are significantly underexpressed in primary Sjögren’s syndrome (pSS) patients compared with both non-pSS sicca patients and controls.
Note that the Salmon module (446 genes) differs from the other two modules with respect to the non-pSS sicca patients, where the module
eigengene is underexpressed compared with controls.
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humans. Importantly for this study, extensive transcrip-
tomic profiling data of salivary glands defining develop-
ment of Sjögren’s syndrome are available.
The module preservation statistics allow one to quantify
which aspects of within-module topology are preserved
between a reference network (human parotid glands) and
a test network (mouse salivary glands). We used two com-
posite preservation statistics (Zsummary and medianRank)
to assess overall module preservation. We evaluated the
preservation of the human modules in the entire mouse
dataset (that is, all weeks together). Strikingly, both statis-
tics revealed that the human Magenta module is the most
highly preserved module in the mouse data (for example,
Zsummary = 11, P <10-18). Further, Additional file 5
demonstrates that the Magenta module eigengene in the
mouse data shows increasing expression across times; that
is, the Magenta genes are significantly (P = 0.034) overex-
pressed in weeks 16 and 20. These results indicate that the
mouse model is appropriate when it comes to an aspect of
the human disease embodied in the Magenta module.
Gene ontology and pathway enrichment analysis
To study the ontology of genes in the seven human pSS
related co-expression modules, we used the Database for
Annotation, Visualization and Integrated Discovery and
the Ingenuity Pathway Analysis software. The enrichment
results are reported in Additional file 2. Here, we highlight
results for the two most significant modules: Magenta and
Turquoise.
For the Magenta module, the top-three over-repre-
sented subcategories within ‘Gene Ontology - Biological
Process’ were immune response (115 genes out of 423
Magenta module genes in both human and mouse data-
sets, P = 1.58 × 10-52, Bonferroni-corrected P = 3.39 ×
10-49), defense response (P = 2.69 × 10-27, Bonferroni-
corrected P = 5.76 × 10-24) and inflammatory response
(46 genes in both human and mouse dataset, P = 1.96 ×
10-17, Bonferroni-corrected P = 4.20 × 10-14). Additional
enriched categories for the Magenta module include anti-
gen processing and presentation (P = 2.95 × 10-17), posi-
tive regulation of response to stimulus (P = 4.30 × 10-17),
cell adhesion molecules (P = 1.34 × 10-13), humoral
immune response (P = 2.38 × 10-13), response to wound-
ing (P = 5.68 × 10-13), lymphocyte activation (P = 2.93 ×
10-11), and cell activation (P = 9.03 × 10-11).
Strikingly, four of the Magenta genes are implicated the
IL-4 signaling pathway (P = 0.025). Figure 4 shows an
Ingenuity Pathway Analysis network plot where genes
colored in grey are part of the Magenta module. Genes
identified include those that encode for Toll-like recep-
tors and their signal transduction molecule MyD88,
molecules that present antigen to natural killer cells (for
example, members of CD1), molecules involved in
immune cell recruitment and adherence (for example,
CCL21, CXCL10, CXCL12, CCR7 and SLAM7), and
molecules responsible for formation of germinal centers
in secondary lymphocyte organs,for example, lympho-
toxin alpha (LTA). CXCL10 (or IP10), CXCL12 (or stro-
mal cell-derived factor-1) and SLAM7 are of particularly
interest as they indicate recruitment of specific leukocyte
subsets - in particular, macrophages, dendritic cells,
T and B lymphocytes, and natural killer cells. We have
independently validated these six genes using quantitative
PCR (Additional file 6).
For the Turquoise module where the genes were
underexpressed in pSS, the top-three over-represented
subcategories within ‘Gene Ontology - Biological Pro-
cess’ were oxidation reduction (P = 7.89 × 10-11, Bonfer-
roni-corrected P = 3.74 × 10-7), generation of precursor
metabolites and energy (P = 4.72 × 10-9, Bonferroni-cor-
rected p = 2.24 × 10-5) and cofactor metabolic process
(P = 1.45 × 10-6, Bonferroni-corrected P = 0.0069). The
category ‘KEGG pathway’ yielded the following top-
three categories: oxidative phosphorylation (P = 9.12 ×
10-7, Bonferroni-corrected P = 1.77 × 10-4), Alzheimer’s
disease (P = 5.66 × 10-6, Bonferroni-corrected P =
0.0011) and Huntington’s disease (P = 3.69 × 10-5, Bon-
ferroni-corrected P = 0.0071).
Additional files 3 and 4 report the results from a stan-
dard differential expression analysis. These look-up
tables allow the user to identify genes strongly related to
disease status in humans and mice, respectively. For
example, Table 2 reports genes with concordant pro-
gression patterns in human and mouse disease. Posi-
tively related genes were selected by requiring a
correlation >0.5 with human progression status (defined
as 0 for controls, 1 for sicca, and 2 for pSS) and a corre-
lation >0.5 with mouse progression status (weeks). Simi-
larly, we selected the negatively correlated genes using a
correlation threshold of -0.5. The corresponding
P values are reported in Table 2. The MM column
(MM.magenta) shows that most of these genes have
concordant pattern with the Magenta module eigengene,
illustrating again that this module contains genes that are
involved in both human and mouse disease pathology.
Discussion
We have utilized a systems approach to identify the mole-
cular and cellular events underlying the pathogenic pro-
cess in parotid glands of pSS patients, and compared the
altered expressed genes and key signaling pathways with
those in the salivary glands of mice that mimic the features
of pSS. Using a robust statistical and bioinformatics tool,
WGCNA, coupled with GO and Ingenuity Pathways Ana-
lysis software, we have clustered hundreds of co-expressed
genes into 19 gene modules. Since the module definition
does not make use of GO information, the modules are
initially named by a color.
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Our analyses highlighted seven co-expressed modules
that were enriched with genes that could discriminate
pSS patients from unaffected individuals using parotid
gland tissue, a prime target in Sjögren’s syndrome
pathogenesis. Interestingly, four of the seven modules -
namely, Magenta, Brown, Light-Cyan and Grey60 - were
positively correlated with the disease status, suggesting
that the genes contained in these modules are overex-
pressed in pSS. On the other hand, Turquoise, Gray and
Salmon modules were negatively correlated with the dis-
ease status, suggesting that the genes in these modules
are underexpressed in pSS.
We acknowledge that clinical samples are not gender-
matched between the Sjögren’s subjects and the non-
Sjögren’s subjects, which may be a potential source of
bias. We have found that gender has a negligible effect
on gene expression levels in the controls. None of the
genes were gender related at a false discovery rate
threshold of 0.05. Of the 5,461 genes that were differen-
tially expressed between pSS cases and controls at a
false discovery threshold of 0.05, only 140 genes showed
differential expression (P <0.05) between males and
females of the control samples. Further, we find that the
vast majority of module genes are on autosomes and
that there is no evidence that gender affects their
expression level in the control group.
When comparing human and mouse data, we found
that the Magenta module was the most highly conserved
module between these two species. Not surprisingly, this
module was enriched with genes involved in immunity
Figure 4 Ingenuity Pathway Analysis software network plot. Genes shaded grey were part of the magenta module and are significantly
altered in the parotid gland of primary Sjögren’s syndrome patients. Test statistics and P values of individual genes can be found in Additional
file 3 (humans) and Additional file 4 (mouse).
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and inflammation - the two cardinal events in pSS
pathogenesis. To our knowledge, we are the first to map
out important intersects between human and mouse
pertaining to key molecules and associated pathways in
pSS. The knowledge gained from this work will enhance
future target-based therapies for this devastating disor-
der. Our novel co-expression module-based comparison
of human and mouse models can be used to judge
whether a given mouse model mirrors the human dis-
ease at the transcriptional level. Future studies could
explore whether other mouse models allow for the pre-
servation of additional human disease-related modules.
Characterizing the molecular and cellular events dur-
ing the progression of pSS from a healthy or even a
non-pSS state remains an important challenge. Because
of the lack of specific molecular markers, it is difficult
to determine which healthy subject or sicca patient will
progress to pSS. The gain in knowledge of these events
can suggest which non-pSS individuals are at risk for
developing pSS. In addition, the knowledge base could
be used to intervene in the progression of disease by
target-based therapies. Surprisingly, such specific regi-
mens are not in place at present, still relying on a few
trials with B-cell-targeted and TNF-directed therapies
evolved from testing on other autoimmune diseases
[6,10,29-32]. Our systems-level analyses of high-
throughput gene expression data can demystify the criti-
cal molecular alterations in pSS pathogenesis.
WGCNA is a tool of systems biology analysis and has
proven to be instrumental in identifying biological path-
ways and key gene constituents in a number of diseases
[16,22,26,33,34]. Our module-based analysis not only
alleviated the multiple testing problems inherent in
microarray data analysis, but also identified biologically
plausible, pSS-related modules that are highly signifi-
cantly enriched with relevant GO categories.
The GO analyses revealed striking correlations, both
positive and negative, between gene modules and disease
status. The most positively correlated Magenta module
was significantly enriched with genes involved in antigen
processing and presentation, and immune and inflam-
matory responses. Antigen processing and presentation
are two important events in innate immunity in relation
to pSS, and our findings support these two phenomena
[31]. Interestingly, a few Magenta genes were found to
be part of the IL-4 signaling pathway, which intercon-
nected with the TNF pathway that has been implicated
in pSS disease progression. The negatively correlated
Turquoise module is enriched with genes underex-
pressed in pSS, including those involved in oxidation
reduction, generation of precursor metabolites and
energy, and cofactor metabolic process. pSS patients are
known to have reduced energy levels, while chronic fati-
gue syndrome is a common extraglandular manifestation
[35]. Our data seem in line with this clinical presenta-
tion of the disease.
A unique feature of the present study is the direct
comparison of the human gene expression data with
that of the Sjögren’s syndrome-susceptible C57BL/6.
NOD-Aec1Aec2 mouse model. Since only the human
disease-related Magenta module was highly significantly
preserved in the mouse data, we focused on the
Magenta module to identify disease-relevant pathways
and target genes common to both species. A majority of
the identified genes were part of the immune response,
whereas a minor fraction was part of the inflammatory
response. Further comparison between overexpressed
genes in human and increasingly expressed genes during
the disease time course in mouse led to the identifica-
tion of CD1, CCR7, CXCL10 (or IP10) CXCL12 (or
stromal cell-derived factor-1), SLAM7 and lymphotoxin
alpha (LTA). These genes are of particular interest as
they indicate recruitment of specific leukocyte subsets -
in particular, macrophages, dendritic cells, T and B lym-
phocytes, and natural killer cells - or are involved in
germinal center formation [36]. These observations pro-
vide a compelling concept that our systems approach
can identify targets and pathways overlapped in human
and mouse, supporting the concept that these overlap-
ping genes and their associated pathways are critical for
pSS disease development and manifestations of clinical
disease. We have independently validated these six
genes using quantitative PCR (Additional file 6).
Conclusion
Weighted gene co-expression network analysis identified
a pSS-related co-expression module that relates to pSS
disease not only in human parotid gland but also in
mouse salivary gland gene expression data. The key
genes that are part of the human-mouse intersection
network are useful for elucidating critical pathways and
molecular alterations dysregulated in pSS pathogenesis,
for highlighting genes that could be a major focus of
rodent-based validation studies, and ultimately for devel-
oping therapeutic targets in this debilitating disease.
This systems biologic study also illustrates how com-
parative WGCNA analysis (based on module preserva-
tion statistics) can be used to assess the suitability of a
rodent model with respect to human disease-related
transcriptional changes.
Additional material
Additional file 1: a table presenting MM membership for human
data. For each gene, the table reports the MM measure, which is also
known as eigengene-based connectivity. Each module gives rise to its
own MM measure; for example, MM denotes the measure for the
magenta module. Columns whose name starts MM report the Pearson
correlation coefficient between the gene expression value and the
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respective module eigengene. For each MM measure (a correlation
coefficient), one can also report a corresponding correlation test P value
based on the Student t test (see columns whose name starts p.MM). For
example, p.MM.magenta reports a two-sided correlation test P value
based on the Student t distribution. Column B reports the original
module assignment based on the hierarchical cluster tree but the
module membership measures were used to select genes for the
functional enrichment analysis.
Additional file 2: a table presenting GO terms for genes in human
pSS-associated co-expression modules. The table reports GO
categories, uncorrected test P values, and corresponding P values that
correct for multiple comparisons using the following methods:
Bonferroni, Benjamini, and the false discovery rate. It also reports the
number of population hits and related count data used to calculate the
hypergeometric test P value. Genes column reports the Affymetrix
probes that were hits for the corresponding GO term. The magenta
module (highlighted in yellow) is of particular interest since it was
preserved in the mouse model.
Additional file 3: a table presenting standard differential expression
analysis in human data. For each gene (transcript), the results of
several two-group comparison tests (carried out with the WGCNA
function standardScreeningBinaryTrait) are reported. The first group
comparison test contrasts females versus males in control subjects only
(columns B through L). The second group comparison test compares
controls versus pSS (columns M through W). The third group comparison
test compares controls versus sicca (columns × through AH). The fourth
group comparison test compares pSS versus sicca (columns AI through
AS). Further, columns AT through AZ report the results of a correlation
test where each gene was correlated with an ordinal variable that
encodes disease status (0 for controls, 1 for sicca, and 2 for pSS). Any
column whose name is preceded by corPearson reports the Pearson
correlation coefficients where the binary grouping variable (for example,
female vs. males) was coded as a binary numeric variable (1 for the first
group, 0 for the second group). The meaning of the first and second
groups can be learned from column t.Student, which reports the Student
t-test statistic. For example, t.Student.F.vs.MGenderInControls shows that
the first group corresponds to females and the second group to males
(among the control samples). Similarly, t.Student.Control.vs.pSS and t.
Student.Control.vs.Sicca show that the first group is comprised of
controls. t.Student.pSS.vs.Sicca shows that the first group is comprised of
pSS patients. Column meanFirstGroup reports the mean expression value
in the first group. FoldChange column reports a signed fold-change
value defined by the ratio meanFirstGroup/meanSecondGroup if
meanFirstGroup >meanSecondGroup. But if meanFirstGroup
<meanSecondGroup, the fold change is defined as minus
meanSecondGroup/meanFirstGroup. SE.FirstGroup reports the standard
error in the first group. AreaUnderROC reports the area under the
receiver operating characteristic curve. pvalueStudent reports the Student
t test P value that corresponds to the Student t-test statistic. q.Student
reports the corresponding q value (local false discovery rate) calculated
with the qvalue R package. nPresentSamples reports the number of
nonmissing observations that were available.
Additional file 4: a table presenting correlations of mouse
expression data with time. This comma-delimited file reports the
results from a correlation test where each mouse gene (transcript) is
correlated with time (measured in weeks). Column corTime reports the
correlation coefficient, column ZCorTime reports the corresponding
Student t-test statistic, and column pValueStudentCorTime reports the
corresponding two-sided Student t test P value. Column
AreaUnderROCCorTime reports the area under the receiver operating
characteristic curve calculated with the function rcorr.cens in the Hmisc R
package.
Additional file 5: a figure showing Magenta module expression in
the mouse data. For each week (x axis) the height of the bar shows the
mean of the magenta module eigengene value (±1 standard error). P
value calculated with the Kruskal-Wallis test, which is a nonparametric
group comparison test. While the magenta module was defined based
on the human data, this plot shows how the corresponding module
eigengene relates to time course in the mouse data. To define the
magenta module eigengene in the mouse data, human genes were
mapped to orthologous mouse genes.
Additional file 6: a figure showing the quantitative real-time PCR
validation in the mouse data. The results of the quantitative RT-PCR
validation analysis involving a select group of genes (CD1D1 ortholog of
CD1D, CCR7, CXCL10, CXCL12, SLAMF9, LTA) are reported. Barplots in the
upper and lower panels correspond to the expression values measured
by microarrays and RT-PCR, respectively. The bars are colored according
to time (weeks). To verify the selected gene expressions (n = 7), aliquots
of salivary gland RNA originally used for the microarray data were
pooled. Each cDNA preparation was quantified by spectrophotometry
and PCR performed. Quantifications were determined by ImageJ. Relative
gene expression values yielded by the PCR arrays are compared directly
with data yielded by the Affymetrix 3’ Expression Array GeneChip Mouse
Genome 430 2.0 arrays. Pooling RNA from each time point prior to cDNA
preparation is thought to be the underlying reason for higher transcript
detection in a couple of RT-PCR reactions (for example, in Cxcl12
samples).
Abbreviations
AECG: American-European Consensus Group; bp: base pair; EULAR: European
League against Rheumatism; GO: gene ontology; H & E: hematoxylin and
eosin; IL: interleukin; MM: module membership; PCR: polymerase chain
reaction; pSS: primary Sjögren’s syndrome; TNF: tumor necrosis factor;
WGCNA: weighted gene co-expression network analysis.
Acknowledgements
The authors thank Prof. JLN Roodenburg, Dr MAW Witjes and Dr KP
Schepman for providing parotid tissues from head and neck cancer patients.
They also thank Nadine Spielmann for helping with data acquisition.
Author details
1School of Dentistry, Dental Research Institute, University of California at Los
Angeles, 10833 Le Conte Avenue, 73-017 CHS, Los Angeles, CA 90095-1668,
USA. 2Department of Oral and Maxillofacial Surgery, University Medical
Center Groningen, University of Groningen, P.O. Box 30.001, Groningen, the
Netherlands. 3School of Medicine, Stanford University, 300 Pasteur Drive,
R241 MC 5324, Stanford, CA 94305, USA. 4School of Dentistry, University of
Minnesota, 7536 Moos HST, 515 Delaware Street SE, Minneapolis, MN 55455,
USA. 5Department of Pathology, Immunology and Laboratory Medicine,
School of Medicine, University of Florida College of Medicine, JHMHSC D6-
33D, 1600 SW Archer Road, Gainesville, FL 32610-0275, USA.
Authors’ contributions
SH, ANMN-H, AV, SAM, SUG, ABP and DTWW participated in the design of
the study. ANMN-H, RPEP, FGMK, AV, CGMK, FKLS, HB and ABP were
involved with the data acquisition. SH, CC, AV, ABP and HZ performed the
statistical analyses. SH, ANMN-H, RPEP, FGMK, AV, CGMK, FKLS, SAM, SUG,
ABP and DTWW drafted the manuscript. All authors read and approved the
final manuscript.
Competing interests
DTWW is the co-founder of RNAmeTRIX Inc., a molecular diagnostic
company. The remaining authors declare that they have no competing
interests.
Received: 20 March 2012 Revised: 5 September 2012
Accepted: 7 September 2012 Published: 1 November 2012
References
1. Fox R: Sjogren’s syndrome. Lancet 2005, 366:321-331.
2. Jonsson R, Moen K, Vestrheim D, Szodoray P: Current issues in Sjogren’s
syndrome. Oral Dis 2002, 8:130-140.
3. Delaleu N, Jonsson R, Koller MM: Sjogren’s syndrome. Eur J Oral Sci 2005,
113:101-113.
4. Meijer JM, Meiners PM, Huddleston Slater JJ, Spijkervet FK, Kallenberg CG,
Vissink A, Bootsma H: Health-related quality of life, employment and
Horvath et al. Arthritis Research & Therapy 2012, 14:R238
http://arthritis-research.com/content/14/6/R238
Page 11 of 12
disability in patients with Sjogren’s syndrome. Rheumatology (Oxford)
2009, 48:1077-1082.
5. Pijpe J, Meijer JM, Bootsma H, van der Wal JE, Spijkervet FK, Kallenberg CG,
Vissink A, Ihrler S: Clinical and histologic evidence of salivary gland
restoration supports the efficacy of rituximab treatment in Sjogren’s
syndrome. Arthritis Rheum 2009, 60:3251-3256.
6. Ramos-Casals M, Tzioufas AG, Stone JH, Siso A, Bosch X: Treatment of
primary Sjogren syndrome: a systematic review. JAMA 2010, 304:452-460.
7. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL,
Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N,
Weisman MH: Classification criteria for Sjogren’s syndrome: a revised
version of the European criteria proposed by the American-European
Consensus Group. Ann Rheum Dis 2002, 61:554-558.
8. Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, Ramos-
Casals M, Dorner T, Bombardieri S, Hachulla E, Brun JG, Kruize AA,
Praprotnik S, Tomsic M, Gottenberg JE, Devauchelle V, Devita S,
Vollenweider C, Mandl T, Tzioufas A, Carsons S, Saraux A, Sutcliffe N, Vitali C,
Bowman SJ: EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI):
development of a consensus patient index for primary Sjogren’s
syndrome. Ann Rheum Dis 2011, 70:968-972.
9. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E,
Gottenberg JE, Bootsma H, Mariette X, Vitali C: EULAR Sjogren’s syndrome
disease activity index: development of a consensus systemic disease
activity index for primary Sjogren’s syndrome. Ann Rheum Dis 2010,
69:1103-1109.
10. Mariette X, Gottenberg JE: Pathogenesis of Sjogren’s syndrome and
therapeutic consequences. Curr Opin Rheumatol 2010, 22:471-477.
11. Chiorini JA, Cihakova D, Ouellette CE, Caturegli P: Sjogren syndrome:
advances in the pathogenesis from animal models. J Autoimmun 2009,
33:190-196.
12. Delaleu N, Nguyen CQ, Peck AB, Jonsson R: Sjogren’s syndrome: studying
the disease in mice. Arthritis Res Ther 2011, 13:217.
13. Hu S, Zhou M, Jiang J, Wang J, Elashoff D, Gorr S, Michie SA, Spijkervet FK,
Bootsma H, Kallenberg CG, Vissink A, Horvath S, Wong DT: Systems biology
analysis of Sjogren’s syndrome and mucosa-associated lymphoid tissue
lymphoma in parotid glands. Arthritis Rheum 2009, 60:81-92.
14. Soyfoo MS, Steinfeld S, Delporte C: Usefulness of mouse models to study
the pathogenesis of Sjogren’s syndrome. Oral Dis 2007, 13:366-375.
15. Cha S, Nagashima H, Brown VB, Peck AB, Humphreys-Beher MG: Two NOD
Idd-associated intervals contribute synergistically to the development of
autoimmune exocrinopathy (Sjogren’s syndrome) on a healthy murine
background. Arthritis Rheum 2002, 46:1390-1398.
16. Zhang B, Horvath S: A general framework for weighted gene co-
expression network analysis. Stat Appl Genet Mol Biol 2005, 4:Article17.
17. Davidoff AM, Pence JC, Shorter NA, Iglehart JD, Marks JR: Expression of p53
gene in human neuroblastoma and neuroepithelioma-derived cell lines.
Oncogene 1992, 7:127-133.
18. Pijpe J, Kalk WW, van der Wal JE, Vissink A, Kluin PM, Roodenburg JL,
Bootsma H, Kallenberg CG, Spijkervet FK: Parotid gland biopsy compared
with labial biopsy in the diagnosis of patients with primary Sjogren’s
syndrome. Rheumatology (Oxford) 2007, 46:335-341.
19. R project. [http://cran.r-project.org/].
20. Johnson WE, Li C, Rabinovic A: Adjusting batch effects in microarray
expression data using empirical Bayes methods. Biostatistics 2007,
8:118-127.
21. Miller JA, Cai C, Langfelder P, Geschwind DH, Kurian SM, Salomon DR,
Horvath S: Strategies for aggregating gene expression data: the
collapseRows R function. BMC bioinformatics 2011, 12:322.
22. Langfelder P, Horvath S: WGCNA: an R package for weighted correlation
network analysis. BMC Bioinformatics 2008, 9:559.
23. Mason MJ, Fan G, Plath K, Zhou Q, Horvath S: Signed weighted gene co-
expression network analysis of transcriptional regulation in murine
embryonic stem cells. BMC Genomics 2009, 10:327.
24. Yip AM, Horvath S: Gene network interconnectedness and the
generalized topological overlap measure. BMC Bioinformatics 2007, 8:22.
25. Langfelder P, Zhang B, Horvath S: Defining clusters from a hierarchical
cluster tree: the Dynamic Tree Cut package for R. Bioinformatics 2008,
24:719-720.
26. Horvath S, Dong J: Geometric interpretation of gene co-expression
network analysis. PLoS Comput Biol 2008, 4:e1000117.
27. DAVID Bioinformatics Resources 6.7. [http://david.abcc.ncifcrf.gov/].
28. Ingenuity Systems. [http://www.ingenuity.com].
29. Meiners PM, Vissink A, Kallenberg CG, Kroese FG, Bootsma H: Treatment of
primary Sjogren’s syndrome with anti-CD20 therapy (rituximab). A
feasible approach or just a starting point? Expert Opin Biol Ther 2011,
11:1381-1394.
30. Kallenberg CG, Vissink A, Kroese FG, Abdulahad WH, Bootsma H: What have
we learned from clinical trials in primary Sjogren’s syndrome about
pathogenesis? Arthritis Res Ther 2011, 13:205.
31. Hansen A, Lipsky PE, Dorner T: Immunopathogenesis of primary Sjogren’s
syndrome: implications for disease management and therapy. Curr Opin
Rheumatol 2005, 17:558-565.
32. Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P: Role of
chemokines in endocrine autoimmune diseases. Endocrine Rev 2007,
28:492-520.
33. Horvath S, Zhang B, Carlson M, Lu KV, Zhu S, Felciano RM, Laurance MF,
Zhao W, Qi S, Chen Z, Lee Y, Scheck AC, Liau LM, Wu H, Geschwind DH,
Febbo PG, Kornblum HI, Cloughesy TF, Nelson SF, Mischel PS: Analysis of
oncogenic signaling networks in glioblastoma identifies ASPM as a
molecular target. Proc Natl Acad Sci USA 2006, 103:17402-17407.
34. Langfelder P, Luo R, Oldham MC, Horvath S: Is my network module
preserved and reproducible? PLoS Comput Biol 2011, 7:e1001057.
35. Segal B, Thomas W, Rogers T, Leon JM, Hughes P, Patel D, Patel K,
Novitzke J, Rohrer M, Gopalakrishnan R, Myers S, Nazmul-Hossain A,
Emamian E, Huang A, Rhodus N, Moser K: Prevalence, severity, and
predictors of fatigue in subjects with primary Sjogren’s syndrome.
Arthritis Rheum 2008, 59:1780-1787.
36. Peck AB, Saylor BT, Nguyen L, Sharma A, She JX, Nguyen CQ, McIndoe RA:
Gene expression profiling of early-phase Sjogren’s syndrome in C57BL/6.
NOD-Aec1Aec2 mice identifies focal adhesion maturation associated
with infiltrating leukocytes. Invest Ophthalmol Vis Sci 2011, 52:5647-5655.
doi:10.1186/ar4081
Cite this article as: Horvath et al.: Systems analysis of primary Sjögren’s
syndrome pathogenesis in salivary glands identifies shared pathways in
human and a mouse model. Arthritis Research & Therapy 2012 14:R238.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Horvath et al. Arthritis Research & Therapy 2012, 14:R238
http://arthritis-research.com/content/14/6/R238
Page 12 of 12
